natgillin/translations-raw huggingface dataset:
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; 5% of 839 patients with NSCLC who were randomised to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomised to receive cisplatin and gemcitabine.
Spodnja preglednica podaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri &gt; 5 % od 839 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in gemcitabin.
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; 5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri &gt; 5 % od 839 bolnikov z nedrobnoceličnim pljučnim rakom, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim pljučnim rakom, ki so naključno prejemali cisplatin in gemcitabin.
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; &gt; 5 % of 839 patients with NSCLC who were randomised to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomised to receive cisplatin and gemcitabine.
Spodnja preglednica podaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri &gt; 5 % od 839 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in gemcitabin.
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; 5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri &gt; 5% od 839 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in gemcitabin.
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in &gt; 5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Spodnja preglednica podaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri &gt; 5 % od 839 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in gemcitabin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.
Spodnja preglednica navaja pogostnost in hudost neželenih učinkov, o katerih so poročali pri &gt; 5 % 168 bolnikov z mezoteliomom, ki so jih naključno razporedili, da so prejemali cisplatin in pemetreksed, ter pri 163 bolnikov z mezoteliomom, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri &gt; 5 % 168 bolnikov z mezoteliomom, ki so jih naključno razporedili, da so prejemali cisplatin in pemetreksed, ter pri 163 bolnikov z mezoteliomom, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed, and 163 patients with mesothelioma randomised to receive single-agent cisplatin.
Spodnja preglednica navaja pogostnost in hudost neželenih učinkov, o katerih so poročali pri &gt; 5 % 168 bolnikov z mezoteliomom, ki so jih naključno razporedili, da so prejemali cisplatin in pemetreksed, ter pri 163 bolnikov z mezoteliomom, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed, and 163 patients with mesothelioma randomised to receive single-agent cisplatin.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri &gt; 5 % 168 bolnikov z mezoteliomom, ki so jih naključno razporedili, da so prejemali cisplatin in pemetreksed, ter pri 163 bolnikov z mezoteliomom, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel.
Spodnja preglednica navaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri &gt; 5 % od 265 bolnikov, ki so jih naključno razporedili, da so prejemali eno učinkovino pemetreksed z dopolniloma folno kislino in vitaminom B12, ter pri 276 bolnikih, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, docetaksel.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 265 patients randomly assigned to receive single-agent pemetrexed with folic acid and vitamin B12 supplementation, and 276 patients randomly assigned to receive single-agent docetaxel.
Spodnja preglednica podaja pogostnost in hudost neželenih učinkov, o katerih so poročali pri &gt; 5 % od 265 bolnikov, ki so jih naključno razporedili, da so prejemali eno učinkovino pemetreksed z dopolniloma folno kislino in vitaminom B12, ter pri 276 bolnikih, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, docetaksel.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 265 patients randomly assigned to receive single-agent pemetrexed with folic acid and vitamin B12 supplementation, and 276 patients randomly assigned to receive single-agent docetaxel.
Spodnja preglednica podaja pogostnost in resnost neželenih učinkov, o katerih so poročali pri &gt; 5 % od 265 bolnikov, ki so jih naključno razporedili, da so prejemali eno učinkovino pemetreksed z dopolniloma folno kislino in vitaminom B12, ter pri 276 bolnikih, ki so jih naključno dodelili v skupino, ki je prejemala le eno učinkovino, docetaksel.
The table lists adverse reactions according to system organ class and frequency: very common (≥1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100) and rare (≥1/10,000 to
Neželeni učinki so v preglednici navedeni glede organske sisteme in pogostost: zelo pogosti (≥1/10), pogosti (od ≥ 1/100 do &lt; 1/10), občasni (od ≥ 1/1,000 do &lt; 1/100) in redki (od ≥1/10,000 do &lt; 1/1,000).
The table presents adverse reactions that occurred with an incidence &gt; 5% if the frequency was higher among Lyxumia treated patients than patients treated with all comparators.
Preglednica prikazuje neželene učinke, ki so se pojavili z incidenco &gt; 5 %, če je bila pogostnost med prejemniki zdravila Lyxumia večja kot med prejemniki vseh primerjalnih zdravil.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina v dveh študijah je bila &gt; 13 g/dl, v drugih treh pa 12–14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina v teh dveh študijah je bila &gt; 130 g/l, v preostalih treh pa od 120 do 140 g/l.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljne koncentracije hemoglobina so bile v dveh študijah &gt; 13 g/dl, v preostalih treh pa 1214 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12- 14 g/dl.
Ciljne koncentracije hemoglobina so bile v dveh študijah &gt; 13 g/dl, v preostalih treh pa 1214 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dL; in the remaining three studies it was 12-14 g/dL.
Ciljna koncentracija hemoglobina v dveh študijah je bila &gt; 13 g/dl, v ostalih treh pa 12-14 g/dL.
The temperature should then be increased to &gt; 39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area.
Nato temperaturo povečamo do &gt; 39°C (toda ne na več kot 40°C) na dveh različnih merilnih mestih v predelu tumorja.
The terminal elimination half-life (t ½ el) values were not significantly different (p &gt; 0.05), with mean values of 31.5 hours and 33.0 hours for the oral paste and the intravenous solution, respectively.
Končni razpolovni čas eliminacije (t ½ el) se ne razlikuje signifikantno (p≥0,05); srednje vrednosti so 31,5 ur in 33,0 ur pri peroralni pasti in intravenski raztopini.
The terminal phase has not been covered unambiguously due to lack of data beyond 24 hours in paediatric subjects &lt; 6 years of age.
Končna faza ni nedvoumno raziskana zaradi pomanjkanja podatkov po 24 urah pri pediatričnih osebah, starih &lt; 6 let.
The third major metabolite, M2, is &gt; 97% bound to plasma proteins.
Tretji glavni presnovek M2 se več kot 97 % veže na beljakovine v plazmi.
The time to first SBM in the LIR subgroup after taking the first dose was shorter for the 25 mg dose as compared to placebo in Kodiac 4 (p &lt; 0.001) and Kodiac 5 (p=0.002).
Čas do prvega spontanega iztrebljanja je bil v podskupini LIR po uporabi prvega odmerka v skupini s 25 mg krajši kot s placebom tako v Kodiac 4 (p &lt; 0,001) kot v Kodiac 5 (p = 0,002).
The toxic range may be characterised by the following results of blood tests: Neutrophils &lt; 2,000/mm3
Za toksično območje so značilni sledeči rezultati krvnih testov:
The toxic range may be characterised by the following results of blood tests: Neutrophils &lt; 2,000/mm3
Za toksično območje so značilni sledeči rezultati krvnih testov: nevtrofilni levkociti &lt; 2.000/mm3
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p &lt; 0.0001).
Koristi zdravljenja z enoksaparinom, ki so se kazale s številnimi izidi učinkovitosti, so se pojavile po 48 urah: ob tem času je bilo relativno tveganje za ponovni miokardni infarkt za 35 % manjše kot z nefrakcioniranim heparinom (p &lt; 0,001).
The treatment difference (raltegravir– efavirenz) was 4.2 % with an associated 95 % CI of (-1.9, 10.3) establishing that raltegravir is non-inferior to efavirenz (p-value for non-inferiority &lt; 0.001).
Razlika med zdravljenjema (raltegravir – efavirenz) je bila 4,2 % (95 % IZ: -1,9, 10,3) in to kaže, da je raltegravir neinferioren efavirenzu (vrednost p za neinferiornost &lt; 0,001).
The trial was stopped early for efficacy reasons as a significantly longer time to relapse (p &lt; 0.0001, Figure 1) was seen in patients treated with Xeplion compared to placebo (hazard ratio = 4.32; 95% CI: 2.4-7.7).
Preskušanje je bilo predčasno prekinjeno zaradi učinkovitosti zdravila, saj so pri bolnikih, ki so se zdravili z zdravilom Xeplion, opazili pomembno daljši čas do relapsa (p &lt; 0,0001, slika 1) kot pri bolnikih, ki so prejemali placebo (razmerje tveganja = 4,32; 95% IZ: 2,4-7,7).
The type and incidence of adverse reactions in patients &gt; 55 years of age were similar to the ones in younger patients (see sections 4.2 and 5.2).
Vrsta in incidenca neželenih učinkov pri bolnikih, starih &gt; 55 let, sta bili podobni kot pri mlajših bolnikih (glejte poglavji 4.2 in 5.2).
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin ( &lt; 35 g/L) as seen in subjects with moderate hepatic impairment.
Delež nevezanega dolutegravirja v plazmi se poveča v primeru nizke koncentracije albumina v serumu ( &lt; 35 g/l), kakršna je opazna pri osebah z zmerno okvaro jeter.
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin ( &lt; 35 g/L) as seen in subjects with moderate hepatic impairment.
Delež nevezanega dolutegravirja v plazmi se pri nizkih vrednostih serumskega albumina ( &lt; 35 g/l) poveča, kar je opazno pri osebah z zmerno okvaro jeter.
The urinary excretion of non-liposomal irinotecan is 11% to 20%; SN-38 &lt; 1%; and
Izločanje neliposomskega irinotekana z urinom je med 11 in 20 %, SN-38 &lt; 1 % in glukuronida
The urinary excretion of unchanged bedaquiline was &lt; 0.001% of the dose in clinical studies, indicating that renal clearance of unchanged active substance is insignificant.
V kliničnih študijah se je manj kot 0,001% odmerka bedakilina izločilo v nespremenjeni obliki z urinom, kar pomeni, da izločanje nespremenjene učinkovine preko ledvic ni pomembno.
The use in patients with acute renal failure or creatinine clearance (CrCl) &lt; 30 ml/min including patients undergoing haemodialysis is contraindicated (see section 4.3).
Uporaba pri bolnikih z akutno ledvično odpovedjo ali z očistkom kreatinina (CrCl) &lt; 30 ml/min, vključno z bolniki na hemodializi je kontraindicirana (glejte poglavje 4.3).
The use in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.4 and 5.2).
Uporaba pri bolnikih s hudo okvaro delovanja ledvic (CLCR &lt; 30 ml/min) ni priporočljiva (glejte poglavji 4.4 in 5.2).
The use of Aclasta in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Aclasta je pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
The use of Aclasta in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Aclasta pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Pri bolnikih s sladkorno boleznijo ali okvaro ledvic (GFR &lt; 60 ml/min/1,73 m2) je sočasna uporaba aliskirena in zaviralcev angiotenzinskih receptorjev II ali zaviralcev ACE kontraindicirana (glejte poglavje 4.3).
The use of Dacogen as initial therapy was also evaluated in an open-label, single-arm, Phase II study (DACO-017) in 55 subjects &gt; 60 years with AML according to the WHO classification.
Uporabo zdravila Dacogen kot prvega zdravila so ocenjevali tudi v odprti študiji faze 2 z eno samo skupino (DACO-017) pri 55 bolnikih, ki so bili stari &gt; 60 let in so imeli AML po klasifikaciji SZO.
The use of Emtricitabine/Tenofovir disoproxil Zentiva is not recommended in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Uporaba zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se ne priporoča pri bolnikih s hudo ledvično okvaro (očistek kreatinina &lt; 30 ml/min) in bolnikih, ki potrebujejo hemodializo, ker ustreznega zmanjšanja odmerka ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 5.2).
The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl &lt; 30ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.3).
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 30 ml/min) ali končno odpovedjo ledvic, pri kateri je potrebna dializa, je uporaba pirfenidona kontraindicirana (glejte poglavji 4.2 in 4.3).
The use of silodosin in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba silodozina pri bolnikih s hudo okvaro delovanja ledvic (CLCR &lt; 30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of silodosin in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba zdravila Silodyx pri bolnikih s hudo okvaro delovanja ledvic (CLCR &lt; 30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of silodosin in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba zdravila Urorec pri bolnikih s hudo okvaro delovanja ledvic (CLCR &lt; 30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of sugammadex in patients with severe renal impairment (including patients requiring dialysis (CrCl &lt; 30 mL/min)) is not recommended (see section 4.4).
Pri bolnikih s hudo ledvično okvaro (vključno s tistimi na dializi (CrCl &lt; 30 ml/min)) uporabe sugamadeksa ne priporočamo (glejte poglavje 4.4).
The use of telmisartan in combination with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Uporaba kombinacije telmisartana in aliskirena je kontraindicirana pri bolnikih s sladkorno boleznijo ali ledvično okvaro (GFR &lt; 60 ml/min/1,73 m2) (glejte poglavje 4.3).
The use of Truvada is not recommended in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Uporaba zdravila Truvada se ne priporoča pri bolnikih s hudo ledvično okvaro (očistek kreatinina &lt; 30 ml/min) in bolnikih, ki potrebujejo hemodializo, ker ustreznega zmanjšanja odmerka ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 5.2).
The use of warm ( &gt; 40°C) or carbonated beverages should be avoided.
Toplim napitkom ( &gt; 40°C) in gaziranim pijačam se je treba izogibati.
The use of Zoledronic Acid Hospira in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Zoledronska kislina Hospira pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved pri tej populaciji.
The use of zoledronic acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population
Uporaba zoledronske kisline je pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji .
The use of zoledronic acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zoledronske kisline pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved pri tej populaciji.
The use of Zoledronic acid Teva Pharma in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Zoledronska kislina Teva Pharma je pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
The use of Zoledronic acid Teva Pharma in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Zoledronska kislina Teva Pharma pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved pri tej populaciji.
The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2 where Cholib is contraindicated (see section 4.3).
Priporoča se običajni odmerek, razen v primeru zmanjšanega delovanja ledvic z ocenjeno hitrostjo glomerulne filtracije &lt; 60 ml/min/1,73 m2, kjer je uporaba zdravila Cholib kontraindicirana (glejte poglavje 4.3).
The vaccine response was defined as the proportion of subjects with: rSBA titres  32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre &lt; 8) at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥ 8)
Odziv na cepivo je bil opredeljen kot delež oseb s: titri rSBA  32 pri uvodoma seronegativnih preskušancih (tj. titer rSBA pred cepljenjem &lt; 8) vsaj 4-kratnim porastom titrov rSBA od pred cepljenja do po cepljenju pri uvodoma seropozitivnih preskušancih (tj. titer rSBA pred cepljenjem ≥ 8)
The VIO study included patients with occult with no classic subfoveal CNV with a visual acuity score of 73-34 letters (20/40-20/200), and patients with lesions &gt; 4 MPS disc areas were to have baseline visual acuity &lt; 65 letters ( &lt; 20/50).
V študijo VIO so bili vključeni bolniki z okultno, a brez klasične subfovealne CNV z oceno vidne ostrine 73-34 črk (20/40-20/200) in bolniki z lezijami, ki so bile večje od 4 MPS površin papile, in izhodiščno vidno ostrino &lt; 65 črk ( &lt; 20/50).
The VIP-AMD included patients with occult with no classic subfoveal CNV with a visual acuity score of &gt; 50 letters (20/100).
V študijo VIP-AMD so bili vključeni bolniki z okultno, a brez klasične subfovealne CNV z oceno vidne ostrine &gt; 50 črk (20/100).
The virologic response rates of the 41 subjects transplanted with HCV RNA &lt; LLOQ is described in Table 17.
Stopnje virološkega odziva za prvih 41 oseb s presaditvijo, z RNA HCV &lt; LLOQ, so navedene v preglednici 17.
The volume of distribution (Vd) for AsIII is large ( &gt; 400 L) indicating significant distribution into the tissues with negligible protein binding.
Volumen porazdelitve (Vd) za AsIII je velik ( &gt; 400 L), kar kaže na značilno porazdelitev v tkivu z zanemarljivo vezavo na beljakovine.
The younger patients with the severe phenotype ( &lt; 2.5 years) and all 4 patients with the intermediate phenotype exhibited a normal rate of mental development, whereas the older patients with a severe phenotype made limited or no gains in cognition.
Mlajši bolniki z resnim fenotipom ( &lt; 2,5 let) in vsi 4 bolniki z vmesnim fenotipom so pokazali normalno stopnjo mentalnega razvoja, medtem ko so starejši bolniki z resnim fenotipom kazali omejen napredek ali nobenega napredka v kogniciji.